Hepatitis B e antigen levels and response to peginterferon: Influence of precore and basal core promoter mutants
Küçük Resim Yok
Tarih
2013
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Elsevier
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Hepatitis B e antigen (HBeAg) levels may predict response to peginterferon (PEG-IFN) but are also influenced by presence of precore (PC) and core promoter (BCP) mutants. HBeAg was measured in 214 patients treated with PEG-IFN +/- lamivudine for 52 weeks. Patients were classified at baseline as wildtype (WT) or non-WT (detectable PC/BCP mutants). Combined response (HBeAg loss with HBV DNA < 2000 IU/mL), HBeAg response (HBeAg loss with HBV DNA > 2000 IU/mL) or non-response was assessed at week 78. Mean baseline HBeAg levels were 2.65 logIU/mL in combined responders, 2.48 in non-responders and 2.24 in HBeAg responders (p F 0.034). Baseline HBeAg levels were not associated with combined response after stratification by WT/non-WT. Within the PEG-IFN monotherapy group (n = 104), patients with HBeAg < 1 logIU/mL at week 24 had a higher probability of combined response (29% versus 12%, p = 0.041). After stratification by WT/non-WT, WT patients with HBeAg < 1 logIU/mL at week 24 had a probability of combined response of 78% (versus 19% in patients with >1 logIU/mL, p < 0.001), whereas no difference in response rates was observed in non-WT patients (p = 0.848). The relationship between HBeAg levels and response to PEG-IFN depends upon the presence of PC/BCP mutants. HBeAg levels should therefore not be routinely used to select patients for PEG-IFN, nor for monitoring of therapy. (C) 2013 Elsevier B.V. All rights reserved.
Açıklama
Anahtar Kelimeler
HBeAg, Peginterferon, Precore, Core promoter, Prediction of response, Immunomodulator
Kaynak
Antiviral Research
WoS Q Değeri
Q1
Scopus Q Değeri
Q1
Cilt
97
Sayı
3
